Fundraising Fox
/Companies
Sign in

StemoniX Medical Tech

Eden Prairie, US · Founded 2014 · Minnesota corporation · 3 known investors

Find your way into StemoniX Medical Tech

Sign up to find every way you can get introduced to StemoniX Medical Tech

  • Your email: who you already know at StemoniX Medical Tech, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the StemoniX Medical Tech team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

28bio (formerly StemoniX Medical Tech) develops human induced-pluripotent-stem-cell-derived 3D neural organoid platforms, including CNS and PNS models, used to measure human neural activity in vitro. The company offers products and services for drug safety assessment, such as seizure liability and neurotoxicity testing, and efficacy research in areas like neuroinflammation, myelination and Alzheimer's disease.

Biotech

Founders & leadership

StemoniX Medical Tech was founded in 2014 by Yung-Ping Yeh.

YY
Yung-Ping YehFounder
RG
Ryan GordonExecutive
MK
Murdoc KhaleghiExecutive
RP
Robert PetcavichNamed on SEC filing

Board

SS
Steven SnyderBoard director
PH
Paul HansenBoard director
KG
Kevin GundersonBoard director

Investors · 3

Brightstone Venture Capitallisted by Brightstone Venture CapitalMinneapolis · $250K – $10M

How we know: Brightstone Venture Capital's portfolio page · funding news · Not right? Tell us

Rockies Venture Clublisted by Rockies Venture ClubDenver · $100K – $500K

Reported raises · per SEC filings

Form D private placements

$14.6M disclosed across 7 rounds · 2015–2020

▶$100KraisedMay 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sriram NadathurDirector
  • Patrick O'ShaughnessyDirector
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Paul HansenDirector
  • Kevin GundersonDirector
  • Andrew LaFrenceExecutive Officer, Promoter
  • Robert PetcavichExecutive Officer, Director, Promoter
Offering amount
$10.9M
Amount sold
$100K
Minimum investment
$25K
Placement agents
Boustead Securities, LLC, North Capital Private Securities Corporation
First sale
May 2020
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedOct 2019 · 31 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Andrew LaFrenceExecutive Officer
  • Blake AnsonExecutive Officer
  • David BucheExecutive Officer
  • Ryan GordonExecutive Officer
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Steven SnyderDirector
  • Fabian ZanellaExecutive Officer
  • Paul HansenDirector
  • Patrick O'ShaughnessyDirector
  • Sriram NadathurDirector
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Murdoc KhaleghiExecutive Officer
  • Kevin GundersonDirector
Offering amount
$6M
Amount sold
$2.1M
Minimum investment
$25K
Sales commissions
$32.3K
Placement agents
Boustead Securities, LLC
First sale
Sep 2019
Incorporated
Corporation, Minnesota
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1.4MraisedAug 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew PerisExecutive Officer
  • Kevin GundersonDirector
  • Dimas JimenezExecutive Officer
  • Marcus BoehmDirector
  • Patrick O'ShaughnessyDirector
  • Steven SnyderDirector
  • Paul HansenDirector
  • David BucheExecutive Officer
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Murdoc KhaleghiExecutive Officer
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Ryan GordonExecutive Officer
Offering amount
$12M
Amount sold
$1.4M
Minimum investment
$10K
First sale
Aug 2018
Incorporated
Corporation, Minnesota, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.9MraisedJun 2018 · 64 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin GundersonDirector
  • Murdoc KhaleghiExecutive Officer
  • Steven SnyderDirector
  • Marcus BoehmDirector
  • Paul HansenDirector
  • Dimas JimenezExecutive Officer
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Patrick O'ShaughnessyDirector
  • David BucheExecutive Officer
  • Ryan GordonExecutive Officer
  • Matthew PerisExecutive Officer
Offering amount
$6M
Amount sold
$4.9M
Minimum investment
$10K
Sales commissions
$86.5K
Placement agents
Roth Capital Partners
First sale
Oct 2017
Incorporated
Corporation, Minnesota, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMar 2017 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Kevin GundersonDirector
  • Paul HansenDirector
  • Ryan GordonExecutive Officer
  • Patrick O'ShaughnessyDirector
  • Steven SnyderDirector
  • Dimas JimenezExecutive Officer
  • Murdoc KhaleghiExecutive Officer
  • Matthew PerisExecutive Officer
  • Marcus BoehmDirector
  • Fabian ZanellaExecutive Officer
Offering amount
$6M
Amount sold
$2.4M
Minimum investment
$10K
Sales commissions
$295K
Placement agents
Cedar Point Capital, LLC
First sale
Feb 2017
Incorporated
Corporation, Minnesota, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedOct 2016 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Marcus BoehmDirector
  • Murdoc KhaleghiExecutive Officer
  • Steven SnyderDirector
  • Paul HansenDirector
  • Ryan GordonExecutive Officer
  • Kevin GundersonDirector
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Yung-Ping YehExecutive Officer, Director, Promoter
Offering amount
$2.5M
Amount sold
$2.5M
Minimum investment
$10K
First sale
Jul 2016
Incorporated
Corporation, Minnesota, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedJan 2016 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan GordonExecutive Officer
  • Steven SnyderDirector
  • Robert PetcavichExecutive Officer, Director, Promoter
  • Yung-Ping YehExecutive Officer, Director, Promoter
  • Paul HansenDirector
  • Kevin GundersonDirector
  • Murdoc KhaleghiExecutive Officer
Offering amount
$2.3M
Amount sold
$1.1M
Minimum investment
$10K
First sale
Dec 2015
Incorporated
Corporation, Minnesota, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does StemoniX Medical Tech do?
28bio (formerly StemoniX Medical Tech) develops human induced-pluripotent-stem-cell-derived 3D neural organoid platforms, including CNS and PNS models, used to measure human neural activity in vitro. The company offers products and services for drug safety assessment, such as seizure liability and neurotoxicity testing, and efficacy research in areas like neuroinflammation, myelination and Alzheimer's disease.
Who founded StemoniX Medical Tech?
StemoniX Medical Tech was founded by Yung-Ping Yeh in 2014.
Who are StemoniX Medical Tech's investors?
StemoniX Medical Tech's investors include Alumni Ventures, Brightstone Venture Capital, Rockies Venture Club.
How much funding has StemoniX Medical Tech raised?
StemoniX Medical Tech has disclosed $14.6M raised across 7 rounds.
Where is StemoniX Medical Tech headquartered?
StemoniX Medical Tech is headquartered in Eden Prairie, US.